{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:40:06Z","timestamp":1787071206358,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The current treatment regimens for Hodgkin\u2019s lymphoma (HL) are associated with high incidences of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of doxorubicin + bleomycin + vincristine + dacarbazine (ABVD) and standard bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone (BEACOPP) chemotherapy in the treatment of advanced stage HL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This multicenter, randomized, parallel, open, positive control noninferiority trial was conducted from 2016 to 2019 and comprised 93 subjects who were randomized in a 1:1 ratio between the treatment (BEACOPP; n = 44) and control (ABVD; n = 49) groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The primary efficacy endpoint of this trial was the objective response rate (ORR) after eight cycles of chemotherapy, which was 100.00% (36\/36) in the treatment group and 95.74% (45\/49) in the control group. The incidence of adverse reactions was 100% in both groups. Significant differences (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) in the incidences of grade 3 (39\/44 [88.64%] vs. 23\/49 [46.94%]) and grade 4 (27\/44 [61.36%] vs. 8\/49 [16.94%]) adverse events were observed between the treatment and control groups, respectively. However, most of these reactions were manageable, with no serious consequences, and were reversible after discontinuation of the treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both regimens had a similar ORR and were associated with a high number of adverse events. The ABVD regimen was better tolerated and safer than the standard BEACOPP regimen. This study indicates that the standard BEACOPP regimen may be considered as a treatment option for patients with advanced HL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_511_23","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:46:50Z","timestamp":1724932010000},"page":"1258-1264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin\u2019s lymphoma"],"prefix":"10.4103","volume":"20","author":[{"given":"Ningjing","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan University, Chengdou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fudan University Shanghai Cancer Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shune","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphomatosis, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Lymphomatosis, The Fifth Medical Center of the Chinese People\u2019s Liberation Army General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Li","sequence":"additional","affiliation":[{"name":"Lee\u2019s Pharmaceutical Limited, Hongkong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Dai","sequence":"additional","affiliation":[{"name":"Lee\u2019s Pharmaceutical Limited, Hongkong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Li","sequence":"additional","affiliation":[{"name":"Lee\u2019s Pharmaceutical Limited, Hongkong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/bjh.16587","article-title":"How I treat advanced Hodgkin lymphoma-A global view","volume":"190","author":"Hokland","year":"2020","journal-title":"Br J Haematol"},{"issue":"Suppl 9","key":"R3-20241021","doi-asserted-by":"crossref","first-page":"ix71","DOI":"10.1093\/annonc\/mdm297","article-title":"Early, intermediate and advanced Hodgkin's lymphoma:modern treatment strategies","volume":"18","author":"Diehl","year":"2007","journal-title":"Ann Oncol"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15622","article-title":"Current treatment paradigms for advanced stage Hodgkin lymphoma","volume":"184","author":"Longley","year":"2019","journal-title":"Br J Haematol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0609.2005.00448.x","article-title":"Hodgkin lymphoma:A curable disease:What comes next?","author":"Diehl","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1470-2045(13)70528-X","article-title":"Can we improve ABVD in Hodgkin's lymphoma?","volume":"14","author":"Gisselbrecht","year":"2013","journal-title":"Lancet Oncol"},{"key":"R8-20241021","first-page":"751","article-title":"Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma","volume":"89","author":"Hohaus","year":"2004","journal-title":"Haematologica"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma:An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.2147\/CMAR.S179356","article-title":"Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults:A network meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial):A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"R12-20241021","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/07357900600981380","article-title":"Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?","volume":"24","author":"Diehl","year":"2006","journal-title":"Cancer Invest"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12185-016-2080-5","article-title":"Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment:A meta-analysis","volume":"104","author":"Jiang","year":"2016","journal-title":"Int J Hematol"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1470-2045(13)70382-6","article-title":"BEACOPP escalated versus ABVD in advanced Hodgkin's lymphoma","volume":"14","author":"Andr\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2016.67.9431","article-title":"HD2000 update in Hodgkin lymphoma-ABVD or BEACOPP?","volume":"34","author":"Vassilakopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17474086.2020.1793666","article-title":"Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma:A systematic literature review","volume":"13","author":"Dalal","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.25871","article-title":"ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma:Results from a multicenter European study","volume":"95","author":"Mondello","year":"2020","journal-title":"Am J Hematol"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles\u22654 baseline):Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.20.02905","article-title":"Time to change direction in the treatment of relapsed hodgkin lymphoma?","volume":"39","author":"Crump","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2015.64.8683","article-title":"ABVD or BEACOPP for advanced Hodgkin lymphoma","volume":"34","author":"Engert","year":"2016","journal-title":"J Clin Oncol"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.2147\/CMAR.S179356","article-title":"Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults:A network meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_511_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:04Z","timestamp":1787067784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_511_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_511_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}